enVVeno Medical Corporation (NVNBW) Stock Analysis

enVVeno Medical Corporation (NVNBW) Healthcare & Pipeline Overview

enVVeno Medical Corporation is a clinical-stage medical device company specializing in bioprosthetic solutions for venous diseases, notably the VenoValve for chronic venous insufficiency. Trading on the OTC market, the company focuses on surgical and non-surgical valve replacement technologies to improve blood flow in the leg, targeting a significant unmet need in vascular care.

What Is the Investment Thesis for NVNBW?

enVVeno Medical Corporation presents a compelling, albeit high-risk, investment opportunity within the medical device sector. The company's focus on addressing Chronic Venous Insufficiency (CVI) with its VenoValve and enVVe products targets a significant unmet need. Successful completion of clinical trials and subsequent regulatory approval for VenoValve could drive substantial revenue growth. Key value drivers include positive clinical trial outcomes, strategic partnerships, and potential acquisition by a larger medical device company. However, the company's reliance on OTC markets and the inherent risks associated with clinical-stage medical device development necessitate careful consideration. The current P/E ratio of -0.01 reflects the company's pre-revenue status.

Based on FMP financials and quantitative analysis

NVNBW Key Highlights

enVVeno Medical Corporation focuses on bioprosthetic solutions for venous diseases, addressing a significant unmet need.

• The company's lead product, VenoValve, is a surgical implant designed to treat Chronic Venous Insufficiency (CVI).
• enVVeno is also developing enVVe, a non-surgical, transcatheter-based replacement venous valve for CVI.
• The company changed its name from Hancock Jaffe Laboratories, Inc. in October 2021 to reflect its focus on venous disease.
• enVVeno Medical Corporation operates with a team of 37 employees, indicating a lean operational structure.

Who Are NVNBW's Competitors?

NVNBW is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NVNBW's Key Strengths?

Proprietary VenoValve technology targeting a specific unmet need.

• Focus on both surgical and non-surgical treatment options for CVI.
• Experienced management team with expertise in medical device development.
• Strong intellectual property portfolio with patents protecting their products.

What Are NVNBW's Weaknesses?

Clinical-stage company with no currently approved products.

• Reliance on successful clinical trial outcomes and regulatory approvals.
• Limited financial resources and dependence on external funding.
• Trading on the OTC market, which may limit liquidity and investor access.

What Could Drive NVNBW Stock Higher?

Data readout from ongoing VenoValve clinical trials, expected within the next 12-24 months.

• Potential FDA submission for VenoValve, contingent on positive clinical trial results, anticipated within the next 2-3 years.
• Continued research and development efforts to expand the product pipeline.
• Pursuit of strategic partnerships with larger medical device companies.
• Efforts to increase market awareness and adoption of VenoValve among healthcare providers.

What Are the Key Risks for NVNBW?

Financial-distress signal — its Altman Z-Score of -9.71 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in ongoing clinical trials.
• Delays in regulatory approvals or rejection of VenoValve by regulatory agencies.
• Competition from established medical device companies with greater resources.
• Limited financial resources and dependence on external funding.
• Risks associated with trading on the OTC market, including limited liquidity and price volatility.

What Are the Growth Opportunities for NVNBW?

• Successful Clinical Trials: The successful completion of ongoing and future clinical trials for VenoValve is a critical growth opportunity. Positive results would validate the device's efficacy and safety, paving the way for regulatory approval and commercialization. The market for CVI treatment is substantial, with millions affected worldwide, representing a significant revenue potential for enVVeno. Timeline: Ongoing clinical trials with potential data readouts within the next 12-24 months.
• Regulatory Approval and Commercialization: Securing regulatory approvals, such as FDA approval in the United States, is essential for commercializing VenoValve and enVVe. Approval would allow enVVeno to market and sell its products, accessing a large patient population in need of effective CVI treatments. The company could establish a direct sales force or partner with established medical device distributors to maximize market penetration. Timeline: Anticipated regulatory submissions within the next 2-3 years, contingent on clinical trial outcomes.
• Expansion of Product Pipeline: enVVeno can expand its product pipeline by developing additional bioprosthetic solutions for other venous diseases or related cardiovascular conditions. This diversification would reduce the company's reliance on a single product and broaden its market reach. Potential areas for expansion include treatments for deep vein thrombosis (DVT) or pulmonary embolism (PE). Timeline: Ongoing research and development efforts with potential new product candidates emerging in the next 3-5 years.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships with larger medical device companies or pharmaceutical firms could accelerate enVVeno's growth. These partnerships could provide access to additional funding, expertise, and distribution channels. An acquisition by a larger player in the medical device industry could also provide a significant return for investors. Timeline: Ongoing discussions with potential partners, with potential deals materializing in the next 1-3 years.
• Market Penetration and Adoption: Increasing market penetration and adoption of VenoValve and enVVe among vascular surgeons and interventional cardiologists is crucial for long-term growth. This can be achieved through targeted marketing campaigns, educational programs, and clinical data presentations at medical conferences. Building strong relationships with key opinion leaders in the field is also essential. Timeline: Continuous efforts to increase market awareness and adoption, with gradual gains expected over the next 3-5 years.

What Are NVNBW's Competitive Advantages?

• Proprietary bioprosthetic valve technology.
• Patents protecting their VenoValve and enVVe designs.
• Clinical data supporting the safety and efficacy of their products.
• First-mover advantage in the development of bioprosthetic venous valves.

What Does NVNBW Do?

enVVeno Medical Corporation, formerly Hancock Jaffe Laboratories, Inc., was founded in 1999 and is based in Irvine, California. The company changed its name in October 2021 to reflect its sharpened focus on venous disease treatments. As a clinical-stage medical device company, enVVeno is dedicated to developing innovative bioprosthetic tissue-based solutions aimed at enhancing the standard of care for patients suffering from venous diseases. Their primary focus is on addressing Chronic Venous Insufficiency (CVI), a condition characterized by impaired blood flow in the veins, particularly in the legs. The company's lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore unidirectional blood flow in the femoral vein. The VenoValve acts as a one-way valve, preventing the backflow of blood and alleviating the symptoms of CVI. In addition to the VenoValve, enVVeno is developing enVVe, a non-surgical, transcatheter-based replacement venous valve, offering a less invasive treatment option for CVI. These products represent the company’s commitment to providing a comprehensive range of solutions for venous disease, catering to both surgical and non-surgical patient needs. enVVeno operates with a team of 37 employees, focusing on research, development, and clinical trials to bring these innovative solutions to market.

What Products and Services Does NVNBW Offer?

• Develop bioprosthetic tissue-based solutions for venous diseases.
• Focus on treating Chronic Venous Insufficiency (CVI).
• Develop the VenoValve, a surgical implant for restoring blood flow in the leg.
• Develop enVVe, a non-surgical, transcatheter-based replacement venous valve.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Seek regulatory approvals for their medical devices.
• Commercialize and market their products to healthcare providers.

How Does NVNBW Make Money?

• Develop and patent bioprosthetic medical devices.
• Conduct clinical trials to prove safety and efficacy.
• Obtain regulatory approvals (e.g., FDA) for commercial sale.
• Market and sell devices to hospitals and surgeons.

What Industry Does NVNBW Operate In?

enVVeno Medical Corporation operates within the medical device industry, specifically targeting the venous disease market. This market is characterized by a growing prevalence of chronic venous insufficiency (CVI) due to aging populations and lifestyle factors. The competitive landscape includes companies developing both surgical and non-surgical treatments for venous disorders. enVVeno's focus on bioprosthetic valve technology positions it within a niche segment of the market, potentially offering a unique solution compared to traditional treatments.

Who Are NVNBW's Key Customers?

• Vascular surgeons who perform venous valve replacement procedures.
• Interventional cardiologists who specialize in minimally invasive venous treatments.
• Hospitals and medical centers that offer venous disease treatment options.
• Patients suffering from Chronic Venous Insufficiency (CVI).

Wall Street analysts project enVVeno Medical Corporation revenue of about $7.0M for fiscal 2026, with EPS near $-35.00.

enVVeno Medical Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.71 places it in the distress zone, a signal of elevated financial risk.

Company Profile

enVVeno Medical Corporation operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Robert A. Berman. NVNBW has traded publicly since 2021.

NVNBW Financials

NVNBW Latest News

No recent news available for NVNBW.

What Investors Ask About enVVeno Medical Corporation (NVNBW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources